We are live on ! Find out more
VIVO

Meridian Bioscience Inc

Delisted

VIVO was delisted on the 30th of January, 2023.

186 hedge funds and large institutions have $541M invested in Meridian Bioscience Inc in 2018 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 68 increasing their positions, 57 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

81% more call options, than puts

Call options by funds: $1.05M | Put options by funds: $581K

59% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 17

19% more repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 57

4% more funds holding

Funds holding: 178186 (+8)

0% more capital invested

Capital invested by funds: $539M → $541M (+$1.72M)

Holders
186
Holders Change
+8
Holders Change %
+4.49%
% of All Funds
4.26%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
27
Increased
68
Reduced
57
Closed
17
Calls
$1.05M
Puts
$581K
Net Calls
+$471K
Net Calls Change
-$504K
Name Holding Trade Value Shares
Change
Change in
Stake
Ameriprise
26
Ameriprise
Minnesota
$3.77M +$63.4K +4,284 +2%
Invesco
27
Invesco
Georgia
$3.55M +$722K +48,764 +24%
Man Group
28
Man Group
United Kingdom
$3.55M +$3.7M +250,125 New
Two Sigma Advisers
29
Two Sigma Advisers
New York
$3.23M -$97.7K -6,600 -3%
GF
30
Gabelli Funds
New York
$2.9M -$59.2K -4,000 -2%
D.E. Shaw & Co
31
D.E. Shaw & Co
New York
$2.83M +$378K +25,574 +15%
Goldman Sachs
32
Goldman Sachs
New York
$2.78M +$675K +45,591 +30%
CIS
33
Connors Investor Services
Pennsylvania
$2.66M -$138K -9,341 -5%
Fifth Third Bancorp
34
Fifth Third Bancorp
Ohio
$2.51M -$1.48M -100,000 -36%
GI
35
GAMCO Investors
Connecticut
$2.48M
LSV Asset Management
36
LSV Asset Management
Illinois
$2.33M +$2.43M +164,100 New
AIM
37
Alambic Investment Management
California
$2.29M +$475K +32,068 +25%
SCA
38
Secor Capital Advisors
New York
$2.29M +$884K +59,720 +58%
GCP
39
GSA Capital Partners
United Kingdom
$2.24M +$989K +66,838 +74%
MIP
40
Mondrian Investment Partners
United Kingdom
$2.2M -$399K -26,935 -15%
TA
41
Teton Advisors
New York
$2.2M
CS
42
Credit Suisse
Switzerland
$2.13M +$22.6K +1,528 +1%
Barrow, Hanley, Mewhinney & Strauss
43
Barrow, Hanley, Mewhinney & Strauss
Texas
$2.12M -$6.53K -441 -0.3%
SIM
44
Spark Investment Management
New York
$2.1M -$864K -58,400 -28%
RA
45
Royce & Associates
New York
$2.08M -$1.5K -101 -0.1%
OAM
46
Oxford Asset Management
United Kingdom
$2.03M +$423K +28,557 +25%
New York State Teachers Retirement System (NYSTRS)
47
New York State Teachers Retirement System (NYSTRS)
New York
$1.94M -$19.2K -1,300 -0.9%
American Century Companies
48
American Century Companies
Missouri
$1.86M -$92.1K -6,221 -5%
PNC Financial Services Group
49
PNC Financial Services Group
Pennsylvania
$1.64M -$15.1K -1,020 -0.9%
RhumbLine Advisers
50
RhumbLine Advisers
Massachusetts
$1.44M +$46.3K +3,130 +3%

VIVO Hedge Fund Activity: Q1 2018 in Review

186 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Meridian Bioscience Inc (VIVO) for Q1 2018, worth a combined $541M — up 0.32% from $539M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new VIVO positions and 17 closed out — a net gain of 10 holders — while 68 added to existing stakes and 57 trimmed.

The largest buyer was AJO LP, adding an estimated $6.27M. The largest seller was Brown Capital Management, cutting an estimated $9.72M.

  • 186 institutional investors held Meridian Bioscience Inc (VIVO) as of Q1 2018, up from 178 in Q4 2017.
  • Funds reported $541M of Meridian Bioscience Inc stock for Q1 2018, up 0.32% quarter-over-quarter.
  • 27 funds opened new Meridian Bioscience Inc positions in Q1 2018 and 17 closed out, a net change of +10 holders.
  • The largest Meridian Bioscience Inc buyer in Q1 2018 was AJO LP, an estimated $6.27M added.
  • The largest Meridian Bioscience Inc seller in Q1 2018 was Brown Capital Management, an estimated $9.72M sold.

Based on aggregated 13F filings for Q1 2018.